Association of syndromes of insulin resistance with coronary artery disease

Coronary Artery Disease

Volumn 16, Issue 8, 2005, Pages 477-480

  LeWinter, Martin M ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Coronary artery disease; Coronary risk factors; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

CARDIOVASCULAR RISK; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33748561781     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200512000-00004     Document Type: Review

References (40)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2:120-126. This is a landmark early study from Framingham. It is perhaps the first population-based study showing the link between DM and CAD.
2. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: The Zutphen Study. J Clin Epidemiol 2001; 54:869-876.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444. This is one of the first modern-era epidemiologic studies of the strong association between DM and CAD. It explores inter-relationships between DM and associated risk factors for CAD.
4. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Int Med 2001; 161:1717-1723. This is an epidemiologic study focusing on women with DM. It is one of several documenting that women with DM have a poorer cardiovascular prognosis than men.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. This is a large-scale epidemiologic study that provides perhaps the most definitive information about excess CAD risk in type 2 DM. The study is extremely well controlled. It provides key data about the interaction between type 2 DM and prior myocardial infarction.
6. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102:1014-1019.
7. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction; data from the GISSI-2 study. J Am Coll Cardiol 1993; 22:1788-1794.
8. Shindler DM, Palmeri ST, Antonelli TA, Sleeper LA, Boland J, Cocke TP, Hochman JS. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36 (Suppl A):1097-1103.
9. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21:69-75.
10. Kuusisto J, Mykannen L, Pyorala K, Laakso M. NIDDM and is metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960-967.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412. An important study relating glycemia to cardiovascular and other DM complications. It shows that glycemia has a complex relationship with risk.
12. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: European Diabetes Epidemiology Group. Lancet 1999; 354:617-621.
13. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed pre-diabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898. This is an important study that follows the course of patients with IR. Its results suggest that CAD develops before overt type 2 DM appears.
14. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease. Circulation 2003; 107:636-650.
15. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92 (Suppl 1):18-26.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor GA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
17. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors then insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101:975-980.
18. McPhillips JB, Barrett-Conner E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990; 131:443-453.
19. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36:553-559.
20. Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97:996-1001.
21. Welin L, Eriksson H, Larsson B, Ohlson L-O, Svardsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 1992; 35:766-770.
22. Ferrara A, Barrett-Conner EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984-1991. Am J Epidemiol 1994; 140:857-869. This study was performed in the Rancho Bernardo population and is one of several with a similar theme. It argues that hyperinsulinemia per se is not a major cardiovascular risk factor in the elderly.
23. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype: a report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 1994; 4:40-45.
24. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985; 15:41-46.
25. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand 1985; 701 (Suppl):38-52.
26. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22 year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98:398-404. This is a large study that had very long follow-up period. It established that hyperinsulinemia is a risk factor for CAD in middle-aged men. The long follow-up qualifies this as a landmark study.
27. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres J-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955-1961.
28. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes mellitus: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 2002; 51:1131-1137.
29. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285:2486-2497.
30. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes 1998; 47:1643-1649.
31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359. This is a key study of the epidemiology of the MS. It demonstrates its remarkably high prevalence in the United States.
32. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
33. Denke MA. Connections between obesity and dyslipidemia. Curr Opin Lipidol 2001; 12:625-628.
34. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al., 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141. This paper combines data from two large epidemiologic studies. It relates the MS to risk of coronary events. The data document the high risk of CAD complications in patients with the MS.
35. Solymoss BC, Bourassa MG, Campeau L, Aniderman A, Marcil M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93:19-164.
36. Marroquin OC, Kip KE, Kelley DE, Johnson D, Shaw LJ, Merz NB, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women. Circulation 2004; 109:714-721.
37. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results from a 25-year follow-up study. Lancet 1992; 340:925-929.
38. Gerstein HC, Yusuf S. Dysglycemia and the risk of cardiovascular disease. Lancet 1996; 347:949-950.
39. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92 (Suppl 1):35-42.
40. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and the risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286:421-426.